(Q38611601)

4 September 2017

The safety and tolerability profile of therapies for the prevention and treatment of osteoporosis in postmenopausal women (English)

1 reference

4 September 2017

0 references

Barry S Komm

1

1 reference

4 September 2017

Diana Morgenstern

series ordinal

2

1 reference

4 September 2017

Luis A Yamamoto

series ordinal

3

1 reference

4 September 2017

Simon N Jenkins

series ordinal

4

1 reference

4 September 2017

language of work or name

English

0 references

publication date

20 October 2015

1 reference

Expert Review of Clinical Pharmacology

4 September 2017

1 reference

4 September 2017

8

1 reference

4 September 2017

6

1 reference

4 September 2017

769-784

1 reference

Management of osteoporosis in postmenopausal women

4 September 2017

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1099432

Ethnic differences in hip fracture: a reduced incidence in Mexican Americans

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1099432

Defining ethnic and racial differences in osteoporosis and fragility fractures

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1099432

European guidance for the diagnosis and management of osteoporosis in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1099432

Update on long-term treatment with bisphosphonates for postmenopausal osteoporosis: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1099432

Results of indirect and mixed treatment comparison of fracture efficacy for osteoporosis treatments: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1099432

Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1099432

Atypical femoral fractures are a separate entity, characterized by highly specific radiographic features. A comparison of 59 cases and 218 controls

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1099432

Increasing occurrence of atypical femoral fractures associated with bisphosphonate use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1099432

Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1099432

Bisphosphonate Use and the Risk of Subtrochanteric or Femoral Shaft Fractures in Older Women

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1099432

Bisphosphonates for osteoporosis--where do we go from here?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1099432

Postmenopausal osteoporosis treatment with antiresorptives: effects of discontinuation or long-term continuation on bone turnover and fracture risk--a perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1099432

Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1099432

Incidence of atypical nontraumatic diaphyseal fractures of the femur

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1099432

Questioning the association between bisphosphonates and atypical femoral fractures

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1099432

Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1099432

Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1099432

The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1099432

Long-term administration of quarterly IV ibandronate is effective and well tolerated in postmenopausal osteoporosis: 5-year data from the DIVA study long-term extension

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1099432

Safety of bisphosphonates in the treatment of osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1099432

The effect of 6 versus 9 years of zoledronic acid treatment in osteoporosis: a randomized second extension to the HORIZON-Pivotal Fracture Trial (PFT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1099432

Zoledronic acid and clinical fractures and mortality after hip fracture

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1099432

Potential mediators of the mortality reduction with zoledronic acid after hip fracture

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1099432

Alendronate and atrial fibrillation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1099432

Impact of bisphosphonates on the risk of atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1099432

Efficacy and safety of risedronate 150-mg once a month in the treatment of postmenopausal osteoporosis: 2-year data

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1099432

Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1099432

Upper gastrointestinal tract safety profile of alendronate: the fracture intervention trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1099432

Oral daily ibandronate prevents bone loss in early postmenopausal women without osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1099432

Seven years of treatment with risedronate in women with postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1099432

Comparative gastrointestinal safety of bisphosphonates in primary osteoporosis: a network meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1099432

Reports of esophageal cancer with oral bisphosphonate use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1099432

Exposure to oral bisphosphonates and risk of esophageal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1099432

Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: case-control analysis within a UK primary care cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1099432

Intravenous bisphosphonates for postmenopausal osteoporosis: safety profiles of zoledronic acid and ibandronate in clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1099432

Monocytes and γδ T cells control the acute-phase response to intravenous zoledronate: insights from a phase IV safety trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1099432

Treatment of postmenopausal osteoporosis with delayed-release risedronate 35 mg weekly for 2 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1099432

Bisphosphonate-induced hypocalcemia: report of 3 cases and review of literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1099432

Salmon calcitonin use and associated cancer risk.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1099432

Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1099432

Update on bone anabolics in osteoporosis treatment: rationale, current status, and perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1099432

Safety of parathyroid hormone for the treatment of osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1099432

Long-term treatment of osteoporosis: safety and efficacy appraisal of denosumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1099432

Denosumab for prevention of fractures in postmenopausal women with osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1099432

Infections in postmenopausal women with osteoporosis treated with denosumab or placebo: coincidence or causal association?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1099432

Denosumab in postmenopausal women with low bone mineral density

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1099432

The effect of three or six years of denosumab exposure in women with postmenopausal osteoporosis: results from the FREEDOM extension

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1099432

A meta-analysis of the effect of strontium ranelate on the risk of vertebral and non-vertebral fracture in postmenopausal osteoporosis and the interaction with FRAX(®).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1099432

Drug rash with eosinophilia and systemic symptoms (DRESS) in patients receiving strontium ranelate

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1099432

A review on strontium ranelate long-term antifracture efficacy in the treatment of postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1099432

Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1099432

Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1099432

Breast cancer and hormone-replacement therapy in the Million Women Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1099432

The million women study: a critique

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1099432

Estrogen and progestogen use in postmenopausal women: 2010 position statement of The North American Menopause Society

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1099432

Bleeding with menopausal hormone therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1099432

Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1099432

Risk of breast cancer by type of menopausal hormone therapy: a case-control study among post-menopausal women in France

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1099432

Lower risk of cardiovascular events in postmenopausal women taking oral estradiol compared with oral conjugated equine estrogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1099432

Hormone therapy dose, formulation, route of delivery, and risk of cardiovascular events in women: findings from the Women's Health Initiative Observational Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1099432

Risk of venous thrombosis with oral versus transdermal estrogen therapy among postmenopausal women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1099432

Transdermal and oral hormone replacement therapy and the risk of stroke: a nested case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1099432

Venous thromboembolism risk in relation to use of different types of postmenopausal hormone therapy in a large prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1099432

The effects of tibolone in older postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1099432

Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1099432

Endometrial cancer and hormone-replacement therapy in the Million Women Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1099432

A 5-year study on the effect of hormone therapy, tibolone and raloxifene on vaginal bleeding and endometrial thickness

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1099432

Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1099432

Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1099432

A 7-year randomized, placebo-controlled trial assessing the long-term efficacy and safety of bazedoxifene in postmenopausal women with osteoporosis: effects on bone density and fracture

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1099432

Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1099432

Safety of bazedoxifene in a randomized, double-blind, placebo- and active-controlled Phase 3 study of postmenopausal women with osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1099432

Safety assessment of raloxifene over eight years in a clinical trial setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1099432

Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1099432

Assessment of the safety of long-term bazedoxifene treatment on the reproductive tract in postmenopausal women with osteoporosis: results of a 7-year, randomized, placebo-controlled, phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1099432

Endometrial profile of bazedoxifene acetate alone and in combination with conjugated equine estrogens in a primate model

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1099432

The selective estrogen receptor modulator bazedoxifene inhibits hormone-independent breast cancer cell growth and down-regulates estrogen receptor α and cyclin D1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1099432

Efficacy of tissue-selective estrogen complex of bazedoxifene/conjugated estrogens for osteoporosis prevention in at-risk postmenopausal women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1099432

Effects of bazedoxifene/conjugated estrogens on the endometrium and bone: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1099432

Endometrial effects of a tissue selective estrogen complex containing bazedoxifene/conjugated estrogens as a menopausal therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1099432

Breast effects of bazedoxifene-conjugated estrogens: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1099432

Evaluation of bazedoxifene/conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic parameters and overall safety profile.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1099432

Relief of vasomotor symptoms with the tissue-selective estrogen complex containing bazedoxifene/conjugated estrogens: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1099432

The recent prevalence of osteoporosis and low bone mass in the United States based on bone mineral density at the femoral neck or lumbar spine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1099432

Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1099432

BMD at multiple sites and risk of fracture of multiple types: long-term results from the Study of Osteoporotic Fractures.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1099432

Bone mineral density thresholds for pharmacological intervention to prevent fractures

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1099432

Patterns of anti-osteoporosis medication use among women at high risk of fracture: findings from the Global Longitudinal Study of Osteoporosis in Women (GLOW).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1099432

Individualizing osteoporosis therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1099432

Declining rates of osteoporosis management following fragility fractures in the U.S., 2000 through 2009.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1099432

Trends in osteoporosis treatment with oral and intravenous bisphosphonates in the United States, 2002-2012.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1099432

A decade of postmenopausal hormone therapy prescribing in the United States: long-term effects of the Women's Health Initiative

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1099432

Bisphosphonates and nonhealing femoral fractures: analysis of the FDA Adverse Event Reporting System (FAERS) and international safety efforts: a systematic review from the Research on Adverse Drug Events And Reports (RADAR) project

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1099432

Incidence of vertebral fracture in europe: results from the European Prospective Osteoporosis Study (EPOS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1099432

Treatment of postmenopausal osteoporosis with odanacatib

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1099432

Odanacatib for the treatment of postmenopausal osteoporosis: development history and design and participant characteristics of LOFT, the Long-Term Odanacatib Fracture Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1099432

Beneficial effects of vitamin D on falls and fractures: is cognition rather than bone or muscle behind these benefits?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1099432

Effect of transdermal teriparatide administration on bone mineral density in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1099432

Evaluation of the efficacy, safety and pharmacokinetic profile of oral recombinant human parathyroid hormone [rhPTH(1-31)NH(2)] in postmenopausal women with osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1099432

Effects of abaloparatide, a human parathyroid hormone-related peptide analog, on bone mineral density in postmenopausal women with osteoporosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1099432

Romosozumab in postmenopausal women with low bone mineral density.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1099432

A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1099432

Menopausal hormone therapy use in 17 European countries during the last decade

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1099432

Intravenous ibandronate injections in postmenopausal women with osteoporosis: One-year results from the dosing intravenous administration study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1099432

Romosozumab in Postmenopausal Women with Osteopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1099432

10.1586/17512433.2015.1099432

21 January 2018

Identifiers

DOI

1 reference

4 September 2017

1 reference